Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel - Abstract

PURPOSE: For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus prednisone leads to superior survival and a higher response rate compared with mitoxantrone plus prednisone.

We analyzed the efficacy of long-term treatment with ≥10 cycles of docetaxel, and validated the risk group classification in predicting overall survival (OS) in Japanese patients with mCRPC.

PATIENTS AND METHODS: Fifty-two patients with mCRPC were administered 55 mg/m2 docetaxel and 8 mg dexamethasone, every 3 or 4 weeks, simultaneously with hormonal therapy and daily oral dexamethasone. They were divided into two groups, short-term (9 or fewer cycles) and long-term (10 or more cycles). Four risk factors including the presence of anemia, bone metastases, significant pain and visceral metastases were utilized for the risk group classification.

RESULTS: Fourteen patients (27%) had an elevation of PSA in spite of docetaxel treatment, while 23 patients (44%) had a decline in PSA level, including 9 patients (17%) whose PSA level declined by ≥50%. The median duration of OS after the initiation of this therapy was 11.2 months in the short-term group and 28.5 months in the long-term group. The good risk group showed a significant difference in OS compared with the intermediate and poor risk groups (P< 0.001). The median number of cycles of treatment was 14, 4 and 3 for each risk group, respectively (p< 0.01).

CONCLUSIONS: The present study indicated that ≥10 cycles of this docetaxel therapy can significantly prolong survival in Japanese men with CRPC. This risk group classification for men with mCRPC at the initiation of this chemotherapy is useful.

Written by:
Kawahara T, Miyoshi Y, Sekiguchi Z, Sano F, Hayashi N, Teranishi J, Misaki H, Noguchi K, Kubota Y, Uemura H.   Are you the author?
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.

Reference: PLoS One. 2012;7(10):e48186.
doi: 10.1371/journal.pone.0048186

PubMed Abstract
PMID: 23118948